| 尚文丽,霍树芬,王洁英,刘凌华,任小平,任亚娟.血清NSE、SCCA及CEA在肺癌早期诊断和预后预测中的应用价值研究[J].,2020,(2):308-312 |
| 血清NSE、SCCA及CEA在肺癌早期诊断和预后预测中的应用价值研究 |
| Application Value of Serum NSE, SCCA and CEA for the Early Diagnosis and Prognostic Prediction of Lung Cancer |
| 投稿时间：2019-05-23 修订日期：2019-06-19 |
| DOI：10.13241/j.cnki.pmb.2020.02.022 |
| 中文关键词: 肺癌 神经元特异性烯醇化酶 鳞状细胞癌抗原 癌胚抗原 预后预测 |
| 英文关键词: Lung cancer Neuron-specific enolase Squamous cell carcinoma antigen Carcinoembryonic antigen Prognostic prediction |
| 基金项目:陕西省科技厅自然科学基础研究项目(2018JM7044)；陕西省卫生健康委员会科研项目(2016D036)；西安市科技计划项目（201805093YX1SF27(8)） |
|
| 摘要点击次数: 1002 |
| 全文下载次数: 779 |
| 中文摘要: |
| 摘要 目的：研究血清神经元特异性烯醇化酶(NSE)、鳞状细胞癌抗原(SCCA)及癌胚抗原(CEA)在肺癌早期诊断和预后预测中的应用价值。方法：选择我院2013年1月~2017年1月收治的110例肺癌患者(肺癌组)及同期96例肺部良性疾病患者(肺良性病组)和85例门诊健康体检者(对照组)。比较各组血清NSE、SCCA及CEA水平，采用受试者工作特征(ROC)曲线分析以上指标对肺癌的诊断价值。结果：肺癌组血清NSE、SCCA、CEA水平高于肺良性病组及对照组，肺良性病组血清NSE、SCCA、CEA水平高于对照组(P<0.05)。肺癌Ⅲ+Ⅳ组血清NSE、SCCA及CEA水平高于Ⅰ+Ⅱ组(P<0.05)。小细胞肺癌组血清NSE水平高于鳞癌组、腺癌组，鳞癌组血清SCCA水平高于腺癌组及小细胞肺癌组，腺癌组血清CEA水平高于鳞癌组及小细胞肺癌组(P<0.05)。NSE<16.0 μg/L者平均无疾病进展生存期(PFS)长于NSE≥16.0 μg/L，SCCA <1.5 μg/L者平均PFS长于SCCA≥1.5 μg/L，CEA <5.0 μg/L平均PFS长于CEA≥5.0 μg/L(P<0.05)。NSE、SCCA和CEA及三者联合诊断肺癌的ROC曲线下面积分别为0.880、0.651、0.830及0.937，NSE+SCCA+CEA联合诊断的曲线下面积高于单个指标单独诊断(P<0.05)。结论：血清NSE、SCCA及CEA对肺癌的诊断有重要的参考价值，且有利于肺癌的分期、分型及预后评价。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the application value of serum neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and carcinoembryonic antigen (CEA) in the early diagnosis and prognosis prediction of lung cancer. Methods: 110 cases of patients with lung cancer (lung cancer group) admitted to our hospital from January 2013 to January 2017, and 96 patients with benign pulmonary diseases (benign lung disease group) and 85 outpatient health examinations (control group). Serum levels of NSE, SCCA and CEA of each group were compared, and the diagnostic value of the above indicators for lung cancer was analyzed using the ROC curve. Results: Serum levels of NSE, SCCA and CEA in lung cancer group were higher than those in benign lung disease group and control group, and serum levels of NSE, SCCA and CEA in benign lung disease group were higher than those in control group (P<0.05). Serum NSE, SCCA and CEA levels in lung cancer III+IV group were higher than those in group I+II (P < 0.05). Serum level of NSE in the small cell lung cancer group was higher than that in the squamous cell carcinoma group and adenocarcinoma group, serum level of SCCA in the squamous cell carcinoma group was higher than that in the adenocarcinoma group and small cell lung cancer group, serum level of CEA in the adenocarcinoma group was higher than that in the squamous cell carcinoma group and urine lung cancer group(P<0.05). Mean progression-free survival (PFS) of patients with NSE<16.0 μg/L was longer than that of patients with NSE≥16.0 μg/L, the average PFS of SCCA <1.5 μg/L was longer than that of SCCA ≥1.5 μg/L, and the average PFS of CEA <5.0 μg/L was longer than that of CEA≥5.0 μg/L(P<0.05). The area under the ROC curve of NSE, SCCA, CEA and the three combined diagnosis of lung cancer respectively was 0.880, 0.651, 0.830, 0.937. The area under the curve of NSE+SCCA+CEA combined diagnosis is higher than the single indicator alone. Conclusion: Serum NSE, SCCA and CEA have important reference value for the diagnosis of lung cancer, and it is conducive to the staging, classification and prognostic evaluation of lung cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
